

**AMENDMENTS TO THE CLAIMS**


Please cancel claims 1, 2, 6 and 8 without prejudice or disclaimer; amend claims 3-5 and 9-15; and add claims 16-20 as follows. The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)
2. (Cancelled)
3. (Currently Amended) A method for preventing and/or treating interstitial cystitis by in a subject comprising administering to a subject in need thereof an therapeutically effective amount of a vitamin D compound, thereby preventing and/or treating interstitial cystitis in said subject.
4. (Currently Amended) The use or method of any one of claim[s] 1 to 3, wherein said interstitial cystitis is characterized by the presence of symptoms of bladder dysfunction and bladder inflammation.
5. (Currently Amended) The use or method of any one of claim[s] 1 to 43 wherein the vitamin D compound is administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations with a second medicament for the treatment of interstitial cystitis.
6. (Cancelled)
7. (Original) A pharmaceutical formulation comprising a vitamin D compound and a pharmaceutically acceptable carrier packaged with instructions for use in the prevention and/or treatment of interstitial cystitis.

8. (Cancelled)

9. (Currently Amended) A kit ~~containing~~comprising a vitamin D compound together with instructions directing administration of said compound to a ~~patient~~subject in need of treatment and/or prevention of interstitial cystitis thereby to treat and/or prevent interstitial cystitis in said patient.

10. (Currently Amended) The ~~use, method, formulation, compound or kit of any one of~~ claim[s 1 to 9]3, wherein said vitamin D compound is a compound of the formula:



wherein:

A<sub>1</sub> is single or double bond;

A<sub>2</sub> is a single, double or triple bond;

X<sub>1</sub> and X<sub>2</sub> are each independently H or =CH<sub>2</sub>, provided X<sub>1</sub> and X<sub>2</sub> are not both =CH<sub>2</sub>;

R<sub>1</sub> and R<sub>2</sub> are each independently OC(O)C<sub>1</sub>-C<sub>4</sub> alkyl, OC(O)hydroxyalkyl, OROC(O)haloalkyl, OAc;


R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each independently hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl, or haloalkyl, or R<sub>3</sub> and R<sub>4</sub> taken together with C<sub>20</sub> form C<sub>3</sub>-C<sub>6</sub> cycloalkyl; and

R<sub>6</sub> and R<sub>7</sub> are each independently C<sub>1</sub>-<sub>4</sub>alkyl or haloalkyl; and

R<sub>8</sub> is H, -COC<sub>1</sub>-C<sub>4</sub>alkyl, -COhydroxyalkyl or -COhaloalkyl; and

pharmaceutically acceptable esters, salts, and prodrugs thereof.

11. (Currently Amended) The ~~use, method, formulation, compound or kit of any one of~~ claim[s 1 to 9]<sup>3</sup>, wherein said vitamin D compound is a compound of the formula:



wherein:

X is H<sub>2</sub> or CH<sub>2</sub>;

R<sub>1</sub> is hydrogen, hydroxy or fluorine;

R<sub>2</sub> is hydrogen or methyl;

R<sub>3</sub> is hydrogen or methyl provided that when R<sub>2</sub> or R<sub>3</sub> is methyl, R<sub>3</sub> or R<sub>2</sub> must be hydrogen;

R<sub>4</sub> is methyl, ethyl or trifluoromethyl;


R<sub>5</sub> is methyl, ethyl or trifluoromethyl;

A is a single or double bond; and


B is a single, E-double, Z-double or triple bond.

12. (Currently Amended) The ~~use, method, formulation, compound or kit~~ according to claim 11, wherein each of R<sub>4</sub> and R<sub>5</sub> is methyl or ethyl.


13. (Currently Amended) The ~~use, method, formulation, compound or kit of any one of~~ claim[s] 1-to-9<sup>10</sup>, wherein said vitamin D compound is 1,3-Di-O-acetyl-1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-nor-cholecalciferol, having the formula:



14. (Currently Amended) The ~~use, method, formulation, compound or kit of any one of~~ claim[s] ~~1 to 911~~, wherein said vitamin D compound is 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, having the formula:



15. (Currently Amended) The use, method, formulation, compound or kit of any one of claim[s] 1 to 910, wherein said compound is 1,3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23E-ene-26,27-hexafluoro-19-nor-cholecalciferol, having the formula:



16. (New) The method of claim 3, wherein said vitamin D compound is administered as a pharmaceutical composition comprising a therapeutically effective amount of the vitamin D compound and a pharmaceutically acceptable diluent or carrier therefore.

17. (New) The method of claim 3, wherein the subject is a mammal.

18. (New) The method of claim 17, wherein the mammal is a human.

19. (New) The pharmaceutical formulation of claim 7, wherein the instructions for use are in accordance with the method of claim 3.

20. (New) The pharmaceutical formulation of claim 9, wherein the instructions are in accordance with the method of claim 3.